Dr. Madduri on Eligibility for CAR T-Cell Therapy in Myeloma

Deepu Madduri, MD
Published: Wednesday, Aug 22, 2018



Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses eligibly criteria for patients with multiple myeloma to receive chimeric antigen receptor (CAR) T-cell therapy.

There have been very promising data published recently on the use of CAR T-cell therapy for patients with myeloma, says Madduri. The anti-BCMA CAR T-cell therapy bb2121 was granted a breakthrough therapy designation for previously treated patients with relapsed/refractory myeloma in November 2017.

Madduri says that the biggest challenge with CAR T-cell therapy for these patients is slot limitation. There are many patients who want to receive CAR T-cell therapy, but it is a matter of how many slots are available, as well as eligibility. To be eligible for CAR T-cell therapy, a patient with myeloma must have received a proteasome inhibitor, an immunomodulatory drug, and a CD38 antibody. Additionally, the patient must have good hematological counts, and be relapsed and refractory. The patient cannot have had prior BCMA therapy. Madduri says that it is a matter of qualifying at the right time and the number of slots available.
SELECTED
LANGUAGE


Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses eligibly criteria for patients with multiple myeloma to receive chimeric antigen receptor (CAR) T-cell therapy.

There have been very promising data published recently on the use of CAR T-cell therapy for patients with myeloma, says Madduri. The anti-BCMA CAR T-cell therapy bb2121 was granted a breakthrough therapy designation for previously treated patients with relapsed/refractory myeloma in November 2017.

Madduri says that the biggest challenge with CAR T-cell therapy for these patients is slot limitation. There are many patients who want to receive CAR T-cell therapy, but it is a matter of how many slots are available, as well as eligibility. To be eligible for CAR T-cell therapy, a patient with myeloma must have received a proteasome inhibitor, an immunomodulatory drug, and a CD38 antibody. Additionally, the patient must have good hematological counts, and be relapsed and refractory. The patient cannot have had prior BCMA therapy. Madduri says that it is a matter of qualifying at the right time and the number of slots available.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x